Document:

exhibit_4-36.htm

Exhibit 4.36

 

MANUFACTURING SERVICES AGREEMENT FOR PBT 434 SUPPLY

	  	 	  
	  	This MANUFACTURING SERVICES AGREEMENT (hereinafter called “Agreement”) is made on 28th day of March, 2014 by and between Prana Biotechnology Ltd ACN 080 699 065 (“Prana”), a company incorporated in Australia whose registered office and principal place of business is at Level 2, 369 Royal Parade, Parkville Victoria 3052 and Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a company incorporated and existing under the laws of India, having its principal place of business at # 8-2-337, Road No.3, Banjara Hills, Hyderabad 500 034, Andhra Pradesh, India.
	  	 	  
	
Dr. Reddy’s and Prana are individually referred to as a “Party” and jointly as the “Parties”.

	  	 	  
	
WHEREAS:

	  	 	  
	
A.

	The parties executed a Confidentiality Agreement dated 19th August 2013 and Letter of Intent dated 24th January, 2014 in relation to Prana’s requirement for Dr. Reddy’s to undertake process development, analytical method validations, cGMP manufacture and stability studies of Prana’s compound known as PBT 434.
	  	 	  
	
B.

	The parties now enter this manufacturing services agreement to definitively record all the terms and conditions upon which Dr. Reddy’s will perform the Project.
	  	 	  
	
NOW THEREFORE, IN CONSIDERATION TO THE MUTUAL COVENANTS AGREED HEREIN THE PARTIES HERETO HAVE AGREED TO BE LEGALLY BOUND BY THE FOLLOWING TERMS, WHICH SHALL HEREAFTER GOVERN THE TERMS OF THIS AGREEMENT

	  	 	  
	
1.

	Definitions
	  	 	  
	  	 	
For the purposes of this Agreement, capitalized terms, whether used in the singular or plural, shall have the following meanings, unless the context clearly requires otherwise:

	  	 	  	  
	  	 	
(a)

	
“Affiliate” shall mean, with respect to a Party, any entity controlling, controlled by, or under common control with such Party. For these purposes, “control” shall refer to: (i) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract or otherwise; or (ii) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of an entity.

	  	 	  	  
	  	 	
(b)

	
“Agreement” means this agreement and includes any schedule or annexure to it.

	
DRL IRN – 100004118

	
 

	 	 

 

  

1

  

	  	
(c)

	“API” means an active pharmaceutical ingredient of the Compound.
	  	  	 	  
	  	
(d)

	“Approved Purposes” for a given Party means the performance of the Project and its obligations under this Agreement, and for Prana also means the use of the Compound and Results for its business purposes which will necessarily include the satisfaction of any regulatory requirements in relation to the Compound.
	  	  	 	  
	  	
(e)

	“Business Day” means a day other than Saturday, Sunday or a public holiday or bank holiday in the place where an act is to be performed or a payment is to be made.
	  	  	 	  
	  	
(f)

	“Commencement Date” means 25th October, 2013.
	  	  	 	  
	  	
(g)

	“Compound” or “PBT434” means 5,7-dichloro-2-((ethylamino)methyl)-8-hydroxy-3- methylquinazolin-4(3H)-one hydrobromide.
	  	  	 	  
	  	
(h)

	“Confidential Information” means Dr. Reddy’s Confidential Information or Prana Confidential Information as the context allows.
	  	  	 	  
	  	
(i)

	“Deliverables” means the quantities of Compound, reports, materials, licences or other deliverables specified in the Scope of Project Works for each Sub-Project.
	  	  	 	  
	  	
(j)

	“Dr. Reddy’s Background IP” means all Intellectual Property owned or controlled by or licensed to Dr. Reddy’s or any Affiliate of it as at the Commencement Date.
	  	  	 	  
	  	
(k)

	“Dr. Reddy’s Confidential Information” means:
	  	  	 	  
	  	  	 	
(i)

	
the Proposal (excluding any Prana Confidential Information contained in it);

	  	  	 	  	  
	  	  	 	
(ii)

	
Dr. Reddy’s Background IP;

	  	  	 	  	  
	  	  	 	
(iii)

	
all information concerning Dr. Reddy’s comprising its research projects, plans and strategies, trade secrets, know-how, technology, business operations and financial dealings which is or has been disclosed to or obtained by Prana prior to or after the date of this Agreement (whether orally, electronically or in writing) other than Prana Confidential information and information that Prana can establish:

	  	  	 	  	  	  
	  	  	 	  	
(A)

	
was already in the public domain at the time of its provision to Prana; or

	  	  	 	  	  	  
	  	  	 	  	
(B)

	
became part of the public domain after its provision to Prana, otherwise than though a disclosure by Prana or any person to whom Prana has disclosed Dr. Reddy’s Confidential Information;

	
DRL IRN – 100004118

	
 

	 	 

 

  

2

  

	  	  	 	  	
(C)

	
is or came lawfully into the possession of Prana otherwise than as a result of disclosure in breach of an obligation of confidence; or

	  	  	 	  	  	  
	  	  	 	  	
(D)

	
was independently discovered by Prana without the aid, application or use of the Dr. Reddy’s Confidential Information.

	  	  	 	  	  	  
	  	
(1)

	
“Force Majeure Event” has the meaning given to it in clause 13.

	  	  	  
	  	
(m)

	
“GMP” or “cGMP” means the current good manufacturing practices, standards and requirements specified in US 21 CFR parts 210 and 211 and ICH Q7.

	  	  	  
	  	
(n)

	
“Intellectual Property” (“IP”) means any and all Technology and all intellectual, industrial and commercial property rights throughout the world subsisting in or in relation thereto including rights and interests in respect of or in connection with Patents, trade secrets, rights in confidential information, copyright (including future copyright and rights in the nature of or analogous to copyright), trade marks, service marks, database rights, designs, whether or not registered or registrable and includes applications for any of the foregoing and the right to apply for any of the foregoing in any part of the world.

	  	  	  
	  	
(o)

	
“Letter of Intent” or “LOI” means the Letter of Intent between the parties in relation to the Project dated 24th January, 2014.

	  	  	  
	  	
(p)

	
“Material Form” in relation to information, includes any form (whether visible or not) of storage from which the information can be reproduced, and any form in which the information is embodied or encoded and in relation to Prana Materials, means the materials themselves.

	  	  	  
	  	
(q)

	
“Patents” mean all patent applications, patents, or letters patents, and any claims in any such patent applications or patents, in any part of the world, including, without limitation, all continuations, continuation-in-parts, reissues, extensions, substitutions, confirmations, registrations, re-validations, and additions, and any supplementary protection certificates in respect thereof.

	  	  	  
	  	
(r)

	
“Prana Arising IP” means all Intellectual Property generated, developed, conceived, created, invented, discovered, derived, modified, improved or adapted by Dr. Reddy’s, Prana or their respective Affiliates and Representatives in the course of performing the Project.

	  	  	  
	  	
(s)

	
“Prana Background IP” means all Intellectual Property owned or controlled by or licensed to Prana or any Affiliate of it as at the Commencement Date.

	  	  	  
	  	
(t)

	
“Prana Confidential Information” means: 

	 	 	 
	 	 	 	(i)	the Prana Materials;

	
DRL IRN – 100004118

	
 

	 	 

 

  

3

  

 

	  	  	 	
(ii)

	
the Results and Deliverables;

	  	  	 	  	  	  
	  	  	 	
(iii)

	
the RFP;

	  	  	 	  	  	  
	  	  	 	
(iv)

	
Prana Background IP and Prana Arising IP;

	  	  	 	  	  
	  	  	 	
(v)

	
all information concerning Prana, the Compound and Prana’s research projects, plans and strategies, products, materials and compounds, trade secrets, know how, technology, business operations and financial dealings which is or has been disclosed to or obtained by Dr. Reddy’s prior to or after the date of this Agreement (whether orally, electronically or in writing) other than information that Dr. Reddy’s can establish:

	  	  	 	  	  	  
	  	  	 	  	
(A)

	
was already in the public domain at the time of its provision to Dr. Reddy’s; or

	  	  	 	  	  	  
	  	  	 	  	
(B)

	
became part of the public domain after its provision to Dr Reddy’s, otherwise than though a disclosure by Dr. Reddy’s or any person to whom Dr. Reddy’s has disclosed Prana Confidential Information;

	  	  	 	  	  	  
	  	  	 	  	
(C)

	
is or came lawfully into the possession of Dr. Reddy’s otherwise than as a result of disclosure in breach of an obligation of confidence; or

	  	  	 	  	  	  
	  	  	 	  	
(D)

	
was independently discovered by Dr. Reddy’s outside the Project without the aid, application or use of the Prana Confidential Information.

	  	  	 	  	  	  
	  	
(u)

	“Prana Materials” means:
	  	  	 	  	  	  
	  	  	 	
(i)

	
samples of the Compound in the possession of Dr. Reddy’s as at the Commencement Date and any other materials including reference standards provided by Prana to Dr. Reddy’s for the purpose of the Project; and

	  	  	 	  	  	  
	  	  	 	
(ii)

	
any APIs of the Compound or other materials manufactured by Dr. Reddy’s in the course of the Project.

	  	  	 	  	  	  
	  	
(v)

	“Project” means a process development and manufacturing project to carry out (by way of Sub-Projects)process development, analytical method validations, cGMP manufacture and Stability Studies of the Compound.
	  	  	 	  	  	  
	  	
(w)

	“Project Price” means US$300,000 (subject to an increase of $20,000 if the bonus payment for Project item 6 specified in Appendix A becomes payable).

	
DRL IRN – 100004118

	
 

	 	 

 

  

4

  

 

	  	
(x)

	“Project Works” means the works (comprising the Sub-Projects) described in Appendix A and specified in detail in Appendix B.
	  	  	 	  
	  	
(y)

	“Proposal” means Dr. Reddy’s proposal for PBT434 manufacture provided in response to the RFP. The proposal is set out in Dr. Reddy’s letter dated 3rd October, 2013.
	  	  	 	  
	  	
(z)

	“Quality Agreement” means the quality agreement put in place pursuant to the Manufacturing Service Agreement of PBT 2 HCI Supply dated 19th August, 2013 that will be modified and updated to support this Agreement (attached as Appendix C to this Agreement).
	  	  	 	  
	  	
(aa)

	“Representatives” in relation to a Party means a director, officer, employee, contractor, consultant, agent or adviser of that Party.
	  	  	 	  
	  	
(bb)

	“Results” means:
	  	  	 	  
	  	  	 	
(i)

	
all results, data, information, processes, procedures, methodologies, techniques, concepts, ideas, compounds, materials, items or things conceived, created, developed, discovered, derived, modified, improved or adapted by Dr. Reddy’s or Prana or their respective Affiliates and Representatives during, or as a consequence of, the Project; and

	  	  	 	  	  	  
	  	  	 	
(ii)

	
all papers, materials, records, laboratory notebooks and documents (in written or electronic form) which have been produced by Dr. Reddy’s or Prana or their respective Affiliates and Representatives in relation to the Project and the Results.

	  	  	 	  	  	  
	  	
(cc)

	“RFP” means Prana’s Request for Proposal: Process Development and cGMP API Manufacture of PBT434 dated 19th August 2013.
	  	  	 	  	  	  
	  	
(dd)

	“Scope of Project Works” means the specifications, requirements and Deliverables for the Project Works as set out in Appendix B.
	  	  	 	  	  	  
	  	
(ee)

	“Sub-Projects” means the sub-projects described in Appendix A and specified in detail in Appendix B for performance by Dr Reddy’s, subject in each case to Dr Reddy’s receiving prior written approval from Prana.
	  	  	 	  	  	  
	  	
(ff)

	“Technology” means trade secrets, ideas, knowledge, information, discoveries, inventions, technology, data, results, reports, formulae, techniques, strategies, concepts, methodologies, processes, procedures for experiments and tests and manufacturing scale ups, compounds, materials, methods or schemes for synthesising compounds, uses of/or indications for chemical compounds, technical data, information or specifications, testing methods, assays, isolation and purification methods, designs, sketches, records, biological materials and analyses.

	
DRL IRN – 100004118

	
 

	 	 

 

  

5

  

	  	
(gg)

	
“Timetable” means the timetable contained in Appendix A for the commencement and completion of each Sub-Project.

	  	  	  	  	  
	
2.

	
Engagement and Obligations of Dr. Reddy’s

	  	  	  	  	  
	  	
(a)

	
Prana engages Dr. Reddy’s to perform the Project (to the extent of those Sub-Projects authorised by Prana in accordance with clause 2 (b)), and Dr. Reddy’s agrees to accept the engagement on the terms and conditions contained in this Agreement,

	  	  	  	  	  
	  	
(b)

	
Dr. Reddy’s must receive written authority from Prana’s Head of Discovery and Non-Clinical Development Manager (E. Gautier) or its Principal Scientist (J. Parsons) or its Head of Toxicology (S. Foran) or its Chief Operating Officer (D. Angus) before commencing any Sub-Project. Without such authority for a given Sub-Project, Dr. Reddy’s must not undertake and may not charge Prana its fee for the Sub-Project or any other amount. The work undertaken and the costs of a Sub-Project cannot be altered without the express written permission of Prana. If in relation to a given Sub-Project, Prana provides written authority to undertake the Sub-Project after the relevant commencement date specified in the Timetable, then Dr. Reddy’s shall commence the Sub-Project as soon as is reasonably practicable thereafter, and in any event, not later than 14 days after Prana provides written authority to undertake the Sub-Project.

	  	  	  	  	  
	  	
(c)

	
The parties acknowledge the grant of approval by Prana in the LOI for Dr. Reddy’s to commence Sub-Projects 1, 2 and 3 in Appendix A. The parties also acknowledge and agree to the milestone payments totalling US$76,000 in relation to Sub-Project 3.

	  	  	  	  	  
	  	
(d)

	
Dr. Reddy’s will perform and carry out the Project Works with all due care and skill in accordance with this Agreement, and in particular the Scope of Project Works and the Timetable

	  	  	  	  	  
	  	
(e)

	
Dr. Reddy’s must provide the following updates and reports to Prana:

	  	  	  	  	  
	  	  	
(i)

	
weekly written updates (in a format acceptable to Prana, which will be communicated to Dr. Reddy’s in a separate email) of the work undertaken and the Results obtained for the week, problems encountered by Dr. Reddy’s, the stage of the Timetable that Dr. Reddy’s is up to and any other information that would be relevant to Prana in relation to the Project; and

	
DRL IRN – 100004118

	
 

	 	 

 

  

6

  

 

	  	  	
(ii)

	
a written report (in a format acceptable to Prana) detailing all of the work carried out and all the Results obtained for each Sub-Project undertaken, including all practices, procedures, processes and data (including spectra) and information developed or generated in the conduct of the Sub-Project along with any future recommendations on completion of the work specified in the Scope of Project Works for that Sub-Project.

	  	  	  	  	  
	  	
(f)

	
Dr. Reddy’s will participate in weekly teleconferences with Prana to present its updates and reports and allow Prana to ask any questions that it may have concerning the Project and set the work priorities for the following week. A Representative of Dr. Reddy’s must take the minutes of each telephone conference and prepare these for the consideration and approval of the Parties at the next telephone conference.

	  	  	  	  	  
	  	
(g)

	
All Results arising out of the Project must be recorded in a written format. These results captured in a written format must:

	  	  	  	  	  
	  	  	
(i)

	
be maintained and signed in accordance with best industry practice; and (ii) be made available for inspection by Prana upon request by Prana in writing.

	  	  	  	  	  
	  	
(h)

	
Dr. Reddy’s must comply with cGMP (in relation to the manufacturing work to be undertaken by it) and all applicable laws in the performance of its obligations under this Agreement.

	  	  	  	  	  
	  	
(i)

	
Prana and Dr. Reddy’s have executed the Quality Agreement to the extent required for the purpose of the Project. The Quality Agreement shall be co terminus to this Agreement.

	  	  	  	  	  
	  	
(j)

	
On 15 days prior written notice and not more than twice in each twelve (12) month period, Dr. Reddy’s must allow Prana or any Representative of it to attend any premises at which Project Works are being conducted for the purpose of auditing all Project Works, materials and information to ensure the compliance by Dr. Reddy’s with its obligations under this Agreement. Prana’s Representative shall only have the right to access works, materials and information that relate exclusively to the Project, and only if such access would not compromise Dr. Reddy’s confidentiality obligations to another party and/or its internal QA programs. Notwithstanding the foregoing, if Prana’s Representative is not an employee of Prana, (i) he/she must not be a competitor of Dr. Reddy’s or any of its Affiliates, and (ii) will not be permitted to access or to examine any Project Works, materials and information, until he/she has entered into a non-disclosure agreement with Dr. Reddy’s.

	  	  	  	  	  
	  	
(k)

	
At any time during the conduct of the Project Works with prior notice by Prana, Dr. Reddy’s must allow Prana or any Representative of it to attend any premises at which Project Works are being conducted for the purpose of assessing the progress of the Project Works. Notwithstanding the foregoing, if Prana’s Representative is not an employee of Prana, or Neil Mhaskar or John Devlin (in their capacity as contractors of Prana) (i) he/she must not be a competitor of Dr. Reddy’s or any of its Affiliates, and (ii) will not be permitted to access or to examine any Project works, materials and information, until he/she has entered into a non-­disclosure agreement with Dr. Reddy’s.

	
DRL IRN – 100004118

	
 

	 	 

 

  

7

  

 

	  	
(1)

	
If at any time during or after the termination of this Agreement, Prana requires a third party to perform any work relating to PBT434 including its manufacture, then Dr. Reddy’s must, at the request of Prana, co-operate with Prana and the third party and provide such assistance, advice, documentation and information (including the relevant Results) as is necessary to enable the third party to perform the work requested by Prana. Prana agrees to pay all out-of-pocket expenses reasonably incurred by Dr Reddy’s, provided that any anticipated expenses in excess of USD$1,000 are approved by Prana in writing before they are incurred.

	  	  	  	  	  
	  	
(m)

	
It is agreed in relation to the Deliverables for each Sub-Project that Prana shall have fifteen (15) days (“Testing Period”) from the date they are received to perform acceptance testing on the Deliverables in order to confirm that they comply with the specifications set out in this Agreement (“Acceptance Testing”). If Prana is satisfied that the Deliverables meet specification, then it will confirm this in writing to Dr. Reddy’s and pay the applicable milestone payment. If Prana finds that any Deliverables supplied by Dr. Reddy’s do not meet specification, then Prana will immediately notify Dr. Reddy’s in writing of any non-compliance. If the non-compliance for a Sub-Project relates to:

	  	  	  	  	  
	  	  	
(i)

	
Compound supplied to Prana, then Prana may by written notice:

	  	  	  	  	  
	  	  	  	
(A)

	
require that Dr. Reddy’s manufacture and supply the applicable quantity of Compound based on a manufacture start within 28 days of Prana’s notice or 7 days of initiating plant modification required for the manufacturing, whichever is the earlier and a manufacturing period less than or equal to the period of time originally allocated for the activity in the corresponding Sub-Project in Appendix A; or

	  	  	  	  	  
	  	  	  	
(B)

	
terminate the Sub-Project in whole or in part, in which case Prana will not be liable to pay for, and Dr. Reddy’s must immediately refund any moneys paid by Prana (if any) on account of, the Sub-Project or the terminated part of it;

	  	  	  	  	  
	  	  	
(ii)

	
services or documents or Results supplied, then:

	  	  	  	  	  
	  	  	  	
(A)

	
Prana may require that Dr. Reddy’s immediately repeat the services or re­-write the documents to rectify the non-compliance within the period specified by Prana; or

	  	  	  	  	  
	  	  	  	
(b)

	
terminate the Sub-Project in whole or in part, in which case Prana will not be liable to pay for, and Dr. Reddy’s must immediately refund any moneys paid by Prana (if any) on account of, the Sub-Project or the terminated part of it.

	
DRL IRN - 100004118

	
 

	 	 

 

  

8

  

 

	
3.

	
Payment

	  	  	  	  	  
	  	
(a)

	
The total cost of the Project (including all milestone payments) is three hundred and twenty thousand United States Dollars (USD 300,000/-) for Sub-Projects 1 to 6 inclusive, payable to Dr. Reddy’s. A further bonus payment of US$20,000 may be payable in respect of Sub-Project 6, subject to Dr. Reddy’s complying with the conditions specified in Appendix A for the payment of that sum.

	  	  	  	  	  
	  	
(b)

	
The amount payable by Prana to Dr. Reddy’s for each Sub-Project and the timelines and conditions attaching to each such payment are specified in Appendix A.

	  	  	  	  	  
	  	
(c)

	
All payments are to be made within 30 days of invoicing. Each of the Sub-Projects that attract and satisfy a milestone payment, other than Sub-Project 6(a) Stability Studies, shall be invoiced on completion of the Sub-Project. Each Sub-Project will be invoiced independent of the completion of other Sub-Projects. If any Sub-Project is not authorised by Prana (for whatever reason), then Prana will have no liability to pay Dr. Reddy’s for the Sub-Project fees or any other amount. Sub-Project 6(a) will be invoiced within 30 days of completing the time points mentioned in Appendix A.

	  	  	  	  	  
	  	
(d)

	
All payments are subject to:-

	  	  	  	  	  
	  	  	
(i)

	
Prana having received the requisite Deliverables; and

	  	  	  	  	  
	  	  	
(ii)

	
Completion of the Sub-Project. Completion of a Sub-Project will be determined by the provision of all Deliverables for that Sub-Project that will include the required written documentation, records and Results and relevant materials in the quantities, form and purity as per the Scope of Project Works and satisfactory Acceptance Testing of the Deliverables.

	  	  	  	  	  
	  	
(e)

	
Property in the physical quantity of Compound or any API of it (or any other materials or samples) produced by Dr. Reddy’s under any Sub-Project (Goods) will pass to Prana on delivery of the Compound to Prana’s carrier or payment for the Sub-Project in full, whichever is earlier. At Prana’s request (in case of delay in acceptance of Goods from freight forwarder), Dr. Reddy’s will store the Goods at its cost and at the risk of Prana for up to 90 days at appropriate conditions. In the interim, Dr. Reddy’s will liaise with Prana or its nominee in relation to the transport of the Goods to Prana and will obtain at its own risk and expense any export licence or other official authorisation and carry out where applicable all customs formalities necessary for the export of the Goods. On the agreed date, Dr. Reddy’s will deliver the Goods to Prana’s carrier at Dr. Reddy’s premises at which time risk in the Goods will pass to Prana. The payment amounts mentioned herein do not include freight, insurance and other shipping expenses for transportation of Goods from Dr. Reddy’s premises to Australian port of entry or any other international port (Ex-works shipment) and Prana shall bear all such expenses, and shall reimburse Dr. Reddy’s in full in case Dr. Reddy’s is called upon to incur any such expenses. If requested by Prana, Dr. Reddy’s will help Prana to identify an appropriate freight forwarder.

	
DRL IRN – 100004118

	
 

	 	 

 

  

9

  

	  	
(f)

	
All payments by Prana to Dr. Reddy’s pursuant to this Agreement shall be made without any withholding or deduction of any withholding tax or other tax or mandatory payment to governmental agencies. If Prana is legally required to make any such withholding or deduction from any payment to Dr. Reddy’s under this Agreement, the sum payable by Prana upon which such withholding or deduction is based shall be increased to the extent necessary to ensure that, after such withholding or deduction, Dr. Reddy’s receives and retains, free from liability for such withholding or deduction, a net amount equal to the amount Dr. Reddy’s would have received and retained in the absence of such required withholding or deduction.

	  	  	  	  	  
	
4.

	
Intellectual Property

	  	  	  	  	  
	  	
(a)

	
Dr. Reddy’s acknowledges and agrees that the Prana Background IP will at all times remain the exclusive property of Prana or its relevant Affiliate. Similarly, Prana acknowledges and agrees that the Dr. Reddy’s Background IP will at all times remain the exclusive property of Dr. Reddy’s or its relevant Affiliate.

	  	  	  	  	  
	  	
(b)

	
The Parties acknowledge and agree that all Prana Arising IP is hereby assigned to and will vest in and be solely owned by Prana as and from the time of its creation.

	  	  	  	  	  
	  	
(c)

	
During the term of this Agreement Prana hereby grants Dr. Reddy’s a royalty free, non­ exclusive, non-transferable, revocable licence for the term of this Agreement to use Prana Background IP and Prana Arising IP solely for the Approved Purposes. Similarly, during the term of this Agreement Dr. Reddy’s hereby grants Prana a royalty free, non-exclusive, non-transferable licence to use Dr. Reddy’s Background IP solely for the Approved Purposes.

	  	  	  	  	  
	  	
(d)

	
Dr. Reddy’s will provide all assistance and advice and execute all necessary documents as may be required by Prana from time to time, in relation to:

	  	  	  	  	  
	  	  	
(i)

	
any assignment that may be required to transfer Prana Arising IP to Prana;

	  	  	  	  	  
	  	  	
(ii)

	
any applications by Prana for Patents or other registrable intellectual property rights in respect of the Prana Arising IP; and

	  	  	  	  	  
	  	  	
(iii)

	
any applications, submissions or other documents that Prana seeks to file with a regulatory authority or other government department, agency or body to obtain an approval or consent in relation to the testing, manufacture or sale of the Compound or an API of it, 

	 	 	 	 
	 	 	and Prana shall pay all reasonable costs and expenses incurred by Dr. Reddy’s in providing such assistance.
	  	  	  	  	  
	
5.

	
Term and Termination

	  	  	  	  	  
	  	
(a)

	
This Agreement shall commence on the Commencement Date and shall, subject always to earlier termination under this Clause 5, continue until ninety (90) days after delivery by Dr. Reddy’s to Prana of the final written report for the last Sub-Project approved by Prana.

	
DRL IRN – 100004118

	
 

	 	 

 

  

10

  

	  	
(b)

	
Notwithstanding any other provision of this Agreement, either Party shall have the right at any time by giving notice to the other to terminate this Agreement (or a Sub-Project in the case of the events described in paragraphs (i), (ii) or (iv)) forthwith in any of the following events:

	  	  	  	  	  
	  	  	
(i)

	
if the other Party commits a material breach of this Agreement and the breach is not capable of remedy;

	  	  	  	  	  
	  	  	
(ii)

	
if the other, Party commits a material breach of this Agreement and, where such breach is capable of remedy, that Party does not remedy such breach within 30 days from service of notice upon it that it is in breach and requiring it to remedy such breach; or

	  	  	  	  	  
	  	  	
(iii)

	
if the other Party enters into liquidation, whether compulsory or voluntary (other than for the purposes of solvent reconstruction or amalgamation where the resulting Party assumes all such Party’s obligations under this Agreement), or has a receiver, controller or administrator or similar official appointed over some or all it assets or compounds with its creditors or suffers any similar action in consequence of its indebtedness to creditors; or

	  	  	  	  	  
	  	  	
(iv)

	
if either Party is delayed or incapable of performing its obligations under this Agreement as a result of a matter described in Clause 13 (Force Majeure) for continuous period of 90 days or more.

	  	  	  	  	  
	  	
(c)

	
Notwithstanding any other provision of this Agreement, Prana may terminate this Agreement (in whole or in part) at any time by giving the Dr. Reddy’s 30 days written notice.

	  	  	  	  	  
	  	
(d)

	
The obligations of the Parties under clauses 1, 2 (g) and (l) and (m), 3, 4, 5, 7, 8, 9 (b), 11,15, 16 and 17 will survive the expiry or termination of this Agreement. The obligations of the Parties under clause 6 will survive the expiry or termination of this Agreement for seven (7) years.

	  	  	  	  	  
	  	
(e)

	
On the expiry or termination of this Agreement or on the termination of a Sub-Project and subject to payment of consideration due under this Agreement:

	  	  	  	  	  
	  	  	
(i)

	
Dr. Reddy’s must provide Prana with all outstanding updates and reports as existing at the date of such expiry/termination under clause 2 (e) for any completed or partly completed Sub-Project;

	  	  	  	  	  
	  	  	
(ii)

	
Dr. Reddy’s must deliver to Prana all materials produced by it as part of any completed or partly completed Sub-Project in the quantities, form and purity that complies with Prana’s requirements as set forth in the Scope of Project Works (Appendix B);

	  	  	  	  	  
	  	  	
(iii)

	
Prana must pay all sums which have accrued or been invoiced by Dr. Reddy’s up to the expiry or termination date and are payable in accordance with the terms of this Agreement. If a Sub-Project is only partly completed on the expiry or termination date, then provided this Agreement or the Sub-Project has not been terminated by Prana pursuant to clauses 2 (m) (i) or (ii) or 5 (b)), Dr. Reddy’s will be entitled to a proportion of its fee for that Sub-Project and non-cancellable pass-through expenses necessary to wind down such Sub-Project. Proportion of the fee shall be calculated on the basis of the percentage of the Sub-Project completed by Dr. Reddy’s. If this amount is less than the total of the advance and other progress payments already paid by Prana for the Sub-Project, then Dr. Reddy’s must refund the difference within 30 days of its fee being agreed with Prana.

	
DRL IRN – 100004118

	
 

	 	 

 

  

11

  

	  	  	
(iv)

	
Dr. Reddy’s must return the Prana Materials and all Material Forms of the Prana Confidential Information to Prana. In the case of Prana Materials, the Parties acknowledge and agree that Dr. Reddy’s may retain samples of the Prana Materials manufactured by it so that it may comply with its cGMP obligations;

	  	  	  	  	  
	  	  	
(v)

	
Prana must return all Material Forms of the Dr. Reddy’s Confidential Information to Dr. Reddy’s.

	  	  	  	  	  
	  	
(f)

	
No expiry or termination of this Agreement shall affect any of the rights and obligations of the Parties accrued up to the date of expiry or termination.

	  	  	  	  	  
	
6.

	
Confidentiality

	  	  	  	  	  
	  	
(a)

	
Each Party acknowledges and agrees that the Confidential Information of the other Party will at all times remain the exclusive property of that other Party. Each Party also undertakes to keep the Confidential Information of the other secret and to protect and preserve the confidential nature and secrecy of that Confidential Information.

	  	  	  	  	  
	  	
(b)

	
Prana agrees and acknowledges in relation to Dr. Reddy’s Confidential Information, and Dr. Reddy’s agrees and acknowledges in relation to Prana Confidential Information, that it:

	  	  	  	  	  
	  	  	
(i)

	
may only use or reproduce the other Party’s Confidential Information for the Approved Purposes;

	  	  	  	  
	  	  	
(ii)

	
must not disclose the other Party’s Confidential Information to any person except as permitted by this Agreement;

	  	  	  	  
	  	  	
(iii)

	
must not permit unauthorised persons to have access to the other Party’s Confidential Information;

	  	  	  	  
	  	  	
(iv)

	
must not make, or assist or permit any person (including its Representatives) to make any unauthorised use, disclosure or reproduction of the other Party’s Confidential Information;

	
DRL IRN – 100004118

	
 

	 	 

 

  

12

  

	  	  	
(v)

	
must ensure that any person who has access to the other Party’s Confidential Information does not make any unauthorised use, reproduction or disclosure of that information;

	  	  	  	  
	  	  	
(vi)

	
must enforce the confidentiality obligations imposed or required to be imposed by this Agreement, including diligently prosecuting at its cost any breach or threatened breach of those confidentiality obligations by a person to whom that Party has disclosed the other Party’s Confidential Information and, where appropriate, making applications for interim or interlocutory relief; and

	  	  	  	  
	  	  	
(vii)

	
must provide assistance reasonably requested by the other Party, in relation to any proceedings the other Party may take against any person for unauthorised use, copying or disclosure of the other Party’s Confidential Information.

	  	  	  	  	  
	  	
(c)

	
A Party may disclose the other Party’s Confidential Information to a Representative on a need to know basis but in each case, only to the extent necessary for the Approved Purposes, and provided the Representatives are placed under confidentiality obligations no less onerous than those set out in this Agreement.

	  	  	  
	  	
(d)

	
Each Party must procure that its Representatives (whether or not still employed or engaged in that capacity) do not do or omit to do anything which, if done or omitted to be done by that Party, would breach its obligations under this Agreement.

	  	  	  
	  	
(e)

	
The obligations of confidentiality and non-disclosure contained in this clause 6 do not apply if and to the extent that the Confidential Information is required to be supplied by virtue of any statute, law or regulation. Each Party must notify the other immediately if it becomes aware of any legal requirement to disclose part or all of the other Party’s Confidential Information.

	  	  	  
	  	
(f)

	
Each Party must:

	  	  	  
	  	  	
(i)

	
establish and maintain effective security measures to safeguard the other Party’s Confidential Information from access or use not authorised under this Agreement;

	  	  	  	  
	  	  	
(ii)

	
keep the other Party’s Confidential Information under its own control;

	  	  	  	  
	  	  	
(iii)

	
maintain complete, accurate and up-to-date records of use, copying and disclosure of the other Party’s Confidential Information and immediately produce these records to the other Party, on request; and

	
DRL IRN – 100004118

	
 

	 	 

 

  

13

  

	  	  	
(iv)

	
immediately notify the other Party of any suspected or actual unauthorised use, copying or disclosure of the other Party’s Confidential Information.

	  	  	  	  	  
	  	
(g)

	
Either Party may at any time by notice in writing to the other Party request the return of all Material Forms of its Confidential Information in the possession, power or control of the other Party or any of its Representatives (whether or not those Material Forms were created by the other Party or its Representatives) and the other Party must immediately comply with such request. In the case of Prana Materials to be returned by Dr. Reddy’s, the parties acknowledge and agree that Dr. Reddy’s may retain samples of the Prana Materials manufactured by it so that it may comply with its GMP obligations.

	  	  	  
	  	
(h)

	
Return of the Material Forms of Confidential Information under clause 6(g) does not release a Party from its obligations under this clause 6.

	  	  	  
	
7.

	
Liability

	  	  	  
	  	
(a)

	
Prana will defend, indemnify and hold harmless Dr. Reddy’s and its Representatives and Affiliates from and against any and all liability losses, costs, damages or expenses (including court costs and reasonable attorneys fees) incurred from or arising in connection with any claim (including claims for infringing third party intellectual property rights) arising out of or are in any way relating to:

	  	  	  	  	  
	  	  	
(i)

	
Prana’s use of the Prana Arising IP, the Results, Compound, APIs or any materials produced during a Sub-Project and supplied to Prana, provided Dr. Reddy’s has complied with this Agreement in relation to its performance of the Sub-Project and the Sub-Project Deliverables have been accepted by Prana in writing;

	  	  	  	  	  
	  	  	
(ii)

	
personal injuries or death to persons or property loss or damage which occur on Dr. Reddy’s premises or the premises of Dr. Reddy’s Affiliates as a result of the conduct of the Project to the extent that they are directly attributable to circumstances that could have been avoided by Dr. Reddy’s if it had been aware of relevant information about the Compound that was knowingly or negligently withheld from Dr. Reddy’s by Prana; or

	  	  	  	  	  
	  	  	
(iii)

	
the breach of clauses 4 or 6 by Prana or its Affiliates or Representatives.

	  	  	  	  	  
	  	
(b)

	
Prana will defend, indemnify and hold harmless Dr. Reddy’s and its Representatives and Affiliates from and against any and all liability losses, costs, damages or expenses (including court costs and reasonable attorneys fees) incurred from or arising in connection with any claim for infringing third party intellectual property rights arising out of or are in any way relating to Dr. Reddy’s use, for Approved Purposes, of the Prana Materials, Compound APIs, Prana Background IP or Prana Arising IP.

	
DRL IRN – 100004118

	
 

	 	 

 

  

14

  

	  	  	  	  
	  	
(c)

	
Dr. Reddy’s will indemnify and hold harmless Prana, its Representatives and Affiliates from and against all costs, expenses, liabilities, losses, damages, claims and proceedings suffered or incurred by them (including proceedings for infringing third party intellectual property rights) which have arisen out of or are in any way relating to:

	  	  	  	  
	  	  	
(i)

	
personal injuries or death to persons or property loss or damage which occur on Dr. Reddy’s’ premises or the premises of Dr. Reddy’s’ Affiliates as a result of or in connection with any act or omission, negligence or breach of this Agreement by Dr. Reddy’s or its Affiliates or any of their respective Representatives;

	  	  	  	  
	  	  	
(ii)

	
any use (other than for the Approved Purposes) by Dr. Reddy’s or its Affiliates (or by third parties under licence from or other arrangement with Dr. Reddy’s or its Affiliates) of the Prana Materials, Prana Background IP, the Prana Arising IP, the Results or Compound APIs;

	  	  	  	  
	  	  	
(iii)

	
the use of Dr. Reddy’s Background IP by Prana, its Representatives and Affiliates for the Approved Purposes; or

	  	  	  	  
	  	  	
(iv)

	
the breach of clauses 4 or 6 by Dr. Reddy’s or its Affiliates or Representatives.

	  	  	  	  	  
	  	
(d)

	
Notwithstanding any other provision of this Agreement, neither Party will have any liability to the other Party (or any Affiliate of it) for any consequential or indirect loss or damage (including loss of profits) (“Consequential Loss”) suffered or incurred by the other Party (or any Affiliate of it), howsoever arising This paragraph (e) will not prevent a Party recovering from the other, Consequential Loss suffered or incurred by it (or an Affiliate of it) under paragraphs(a) and (b) and(c) above.

	  	  	  	  	  
	  	
(e)

	
In no event will the aggregate liability of either Party for any claims made by the other Party under or in connection with this Agreement exceed the Project Price (except in relation to their respective liabilities for any claims made under clauses 7 (a), (b) and (c) which will not be subject to this limitation).

	  	  	  	  	  
	
8.

	
Warranties

	  	  	  	  	  
	  	
(a)

	
Each Party warrants to the other that it is duly organised, validly existing and in good standing in accordance with the applicable laws and has all necessary power and authority to enter into this Agreement and to carry out its obligations under this Agreement and to consummate the transactions contemplated hereby and that it is duly licensed or qualified to do business in its principle place of business.

	  	  	  
	  	
(b)

	
Each Party warrants to the other that the execution and delivery by it of this Agreement, the performance by it of its obligations hereunder and the consummation of the transactions contemplated by this Agreement have been duly authorised by all requisite action on the part of the Party, and no other corporate proceedings by it or any of its Affiliates are required in connection therewith.

	  	  	  
	  	
(c)

	
Each Party represents that there is no litigation pending or threatened (judicial, regulatory or otherwise) or other operational issues within its business that would or might prevent or adversely interfere with the performance of its obligations under this Agreement.

	
DRL IRN – 100004118

	
 

	 	 

 

  

15

  

	  	
(d)

	
During the term of this Agreement and before commencing the development and manufacture of the Compound, each Party warrants that it will (at its own cost) obtain, maintain and secure all permits, registrations and licences (including but not limited to those in respect of manufacturing and regulatory) required under applicable laws to allow it to perform its obligations under this Agreement. If requested by a Party, the other Party shall submit copies of any such documents for its inspection and records. Further, the Parties hereby agree that they will promptly notify the other of any notices and non- compliances issues that have been noticed, issued or reported by any regulatory or statutory authorities and ensure that they are complied with immediately without any delay or continuing default.

	  	  	  	  	  
	  	
(e)

	
Each Party warrants that it has the requisite skills, resources, technology and all the rights and licences necessary for rendering services and fulfilling its contractual obligations under this Agreement.

	  	  	  	  	  
	  	
(f)

	
Prana warrants that the Prana Background IP and other information provided by it for use by Dr. Reddy’s in the manufacture and development of the Compound pursuant to this Agreement will not violate or infringe upon the intellectual property rights of any third person. Dr. Reddy’s warrants that the use of Dr. Reddy’s Background IP or other Dr. Reddy’s Confidential Information by either Party for the Approved Purposes will not violate or infringe upon the intellectual property rights of any third person.

	  	  	  	  	  
	  	
(g)

	
EXCEPT AS AGREED UNDER THIS AGREEMENT DR. REDDY’S MAKES NO WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY REGARDING OR RELATING TO THE PERFORMANCE OF THE OBLIGATIONS UNDER THIS AGREEMENT. TO THE EXTENT PERMITTED BY LAW, DR. REDDY’S SPECIFICALLY DISCLAIMS ALL IMPLIED WARRANTIES OR MERCHANTABILITY FOR A PARTICULAR PURPOSE OF RENDERING SERVICES FOR THE PROJECT UNDER THIS AGREEMENT.

	  	  	  	  	  
	
9.

	
Hazardous Information

	  	  	  	  	  
	  	
Prana will make all information (if any) which it has available to it concerning the health and other hazards of the Compound and its synthesisand any other materials including reference standards provided by Prana to Dr. Reddy’s for the purpose of the Project. Dr. Reddy’s must assess these hazards and take the necessary measures in relation to the Project to:

	  	  	  	  	  
	  	
(a)

	
ensure the safety of its Representatives; and

	  	  	  	  	  
	  	
(b)

	
avoid any loss or damage to its premises or property.

	
DRL IRN – 100004118

	
 

	 	 

 

  

16

  

	
10.

	
Assignment and Subcontracting

	  	  	  	  	  
	  	
(a)

	
Neither Party shall assign this Agreement or any of its rights and obligations under it to any third party without first obtaining the prior written consent from the other.(b) Dr. Reddy’s must not subcontract any of its obligations under this Agreement without the prior written consent of Prana.

	  	  	  	  	  
	  	  	  	  	
India

	  	  	  	  	  
	  	  	  	
Plot No. 338, S.V.Co-operative Industrial Estate, Jeedimetla, Hyderabad, Andhra Pradesh, India-500 055)

	  	  	  	  	  
	  	
(c)

	
If Prana, in its absolute discretion, consents to the subcontracting of the performance of any of the Project Works, then:

	  	  	  	  	  
	  	  	
(i)

	
Dr. Reddy’s shall remain fully responsible for the performance of the Project Works and must continue to comply with each and every one of its obligations under this Agreement;

	  	  	  	  
	  	  	
(ii)

	
without limitation, all acts or omissions of the subcontractor shall be deemed acts or omissions of Dr. Reddy’s; and

	  	  	  	  
	  	  	
(iii)

	
Dr. Reddy’s must ensure that any subcontractor so engaged complies with, and enters into a written agreement with Dr. Reddy’s under the terms of which:

	  	  	  	
a.

	
the subcontractor agrees to comply with all relevant provisions of this Agreement (including in respect of performance of the relevant subcontracted Project Works, compliance with cGMP and all applicable laws, record keeping, confidentiality and Intellectual Property) as if it were a party to this Agreement;

	  	  	  	
b.

	
the subcontractor is prohibited itself from subcontracting any part of the performance of the subcontract.

	  	  	  	  	  
	
11.

	
Notices

	  	  	  
	  	
(a)

	
A notice, consent, approval or other communication (each a Notice) under this agreement must be signed by or on behalf of the Party giving it, addressed to the Party to whom it is to be given and:

	  	  	  	  	  
	  	  	
(i)

	
delivered to that Party’s address;

	  	  	  	  
	  	  	
(ii)

	
sent by pre-paid mail to that Party’s address; or

	  	  	  	  
	  	  	
(iii)

	
transmitted by facsimile to that Party’s address.

	
DRL IRN – 100004118

	
 

	 	 

 

  

17

  

 

	  	  	  	  
	  	
(b)

	
A Notice given to a Party in accordance with this clause 10 is treated as having been given and received:

	  	  	  	  
	  	  	
(i)

	
if delivered to a Party’s address, on the day of delivery if a Business Day, otherwise on the next Business Day;

	  	  	  	  
	  	  	
(ii)

	
if sent by pre-paid mail, on the tenth Business Day after posting; or

	  	  	  	  
	  	  	
(iii)

	
if transmitted by facsimile to a Party’s address and a correct and complete transmission report is received, on the day of transmission if a Business Day, otherwise on the next Business Day.

	  	  	  	  
	  	
(c)

	
For the purpose of this clause the address of a Party is the address set out below or another address of which that Party may from time to time give notice to the other Party:

	  	
If to Prana:

	
Dianne Angus

	  	  	
Chief Operating Officer

	  	  	
Prana Biotechnology Ltd

	  	  	
Level 2, 369 Royal Parade, Parkville Victoria 3052

	  	  	  
	  	  	
Facsimile: +61 3 9348 0377

	  	  	  
	  	
If to Dr. Reddy’s:

	
Mr. Anurag Roy

	  	  	
Vice President – Global CPS head

	  	  	
Custom Pharmaceutical Services,

	  	  	
Dr. Reddy’s Laboratories Limited

	  	  	
Bollarum Road, Miyapur,

	  	  	
Hyderabad, Andhra Pradesh, India- 500049

	  	  	  
	  	  	
Facsimile: +91 40 4465 8654

	
12.

	
Entire Agreement

	 	
The Confidentiality Agreement between the Parties dated 19th August 2013, the LOI, the Quality Agreement (as amended pursuant to clause 2 (i)) and this Agreement set forth the entire agreement between the Parties as to its subject matter. In the event of any incompatibility between the terms of this Agreement and the said Confidentiality Agreement LOI and Quality Agreement, the terms of this Agreement shall prevail and take priority. None of the terms of this Agreement shall be amended except in writing signed by both Parties.

 

DRL IRN – 100004118

 

  

18

  

	
13.

	
Force Majeure

	 	
A Party shall not be liable for a failure to perform any of its obligations under this Agreement (other than a payment obligation) due to any cause or circumstance which is beyond its reasonable control, including without limitation, acts of God, wars, riots, interference by military or para-military, strikes, lock-outs or other labour unrest, fires, explosions, shipwrecks, shortage in material if the supplier(s) of such material is unable to supply due to causes and circumstances beyond their control as exemplified above (“Force Majeure Event”) provided always that such failure or delay could not have been prevented by reasonable precautions. In the case of Force Majeure, the obligations of the Party affected shall be suspended and it shall not be liable for damages or for penalties for non-performance to the extent that such non-performance is caused by the Force Majeure event with the proviso that if the Force Majeure period should extend more than three (3) months then the other Party shall have the right to terminate this Agreement forthwith upon written notice at any time after expiration of said three (3) months period. In addition, non-performance shall only be excused during the continuation of the Force Majeure event.

 

	
14.

	
Independent Contractors

	 	 
	 	The parties are independent contractors and this Agreement shall not be construed as creating or evidencing a partnership, agency, employment or joint venture relationship between them.

 

	
15.

	
Dispute Resolution

	  	  	  
	  	
(a)

	
If a dispute arises in connection with this Agreement or relating to this Agreement including its interpretation and any question regarding its existence, validity or termination, then a Party wishing to have the dispute resolved must give the other Party a notice specifying the dispute and requiring its resolution under this clause 15 (“Dispute Notice”).

	  	  	  
	  	
(b)

	
Within 14 days of the date of service of the Dispute Notice, each Party must:

	  	  	  	  
	  	  	
(i)

	
appoint a Representative with authority to negotiate and settle the dispute; and

	  	  	  	  
	  	  	
(ii)

	
notify the other Party in writing of the appointed Representative’s name and contact details.

	  	  	  	  
	  	
(c)

	
The authorised Representatives and the Parties that they represent must then use their reasonable endeavours to resolve the dispute within 42 days of the date of service of the Dispute Notice. If they fail to resolve the dispute within this period, then either Party may institute court proceedings.

	  	  	  	  
	  	
(d)

	
A Party may not commence court or any other proceedings in relation to a dispute arising in connection with this Agreement until it has exhausted the procedures in this clause, unless the Party seeks injunctive or other interlocutory relief to preserve property or rights or to avoid losses that are not compensable in damages.

 

DRL IRN – 100004118

 

  

19

  

 

	  	  	  	  
	
16.

	
Governing Law and Jurisdiction

	  	  
	  	
(a)

	
This Agreement shall be construed, governed, interpreted, and applied in accordance with the laws of England and the courts located at London shall have the exclusive jurisdiction to entertain and resolve all the disputes between the Parties.

	  	  	  
	  	
(b)

	
Each Party irrevocably and unconditionally:

	  	  	  	  
	  	  	
(i)

	
submits to the jurisdiction of the courts of England; and

	  	  	  	  
	  	  	
(ii)

	
waives any claim or objection based on absence of jurisdiction or inconvenient forum.

	  	  	  	  
	  	
(c)

	
The rights and obligations of the parties under this Agreement shall not be governed by the United Nations Convention on Contracts for the International Sale of Goods (1980).

	  	  	  	  
	
17.

	
Miscellaneous

	  	  	  	  
	
(a)

	  	
No forbearance or tolerance on the part of the either Party of any breach of this Agreement by the other shall constitute waiver of the requirements of this Agreement. A right may only be waived in writing, signed by the Party giving the waiver.

	  	  	  
	
(b)

	  	
The parties hereby agree that any provision/s of this agreement which are held to be invalid and unenforceable in law shall not by itself make this Agreement invalid nor effect the other provisions of this agreement and the other terms shall remain fully enforceable and valid in law.

	  	  	  	  
	
(c)

	  	
Each Party agrees to do all things and execute all agreements, instruments, transfers or other documents as may be necessary or desirable to give effect to the provisions of this Agreement and the transactions contemplated by it.

	  	  	  	  
	
(d)

	  	
This Agreement may be executed in any number of counterparts. All counterparts together will be taken to constitute one instrument.

 

DRL IRN – 100004118

 

  

20

  

 

Executed by the Parties by their duly authorised representatives

 

Prana Biotechnology Ltd

	  	  	  
	
By

	 	  	  
	  	  	  
	
(Name): Dianne Angus

	  	  	  
	
(Title): Chief Operating Officer

	  	  	  
	
(Date): 

	  	  

 

Dr. Reddy’s Laboratories Limited

	  	  	  
	
By

	 		  
	  	  	  
	
(Name): Anurag Roy

	  	  	  
	
(Title): Vice President – Head of Global CPS business

	  	  	  
	
(Date):

	
28th March 2014

	  

 

DRL IRN – 100004118

 

  

21

  

Appendix A

 

PROJECT WORKS AND TIMETABLE

 

	

Project item

	 	

Responsible 

Party

	

Milestone 

Payment USD

	

Timeline

	 
	

1-    Sourcing of Raw material (for process development of PBT 434).

 

	 	

Dr. Reddy’s

	  	

Completion date 15th November 2013

	 
	

2-    Submission of Manufacturing License

	 	

Dr. Reddy’s**

	  	  	 
	

3-    Process development of current and proposed route will take place in parallel.

	 	

Dr. Reddy’s

	  	

Commencement date

 

-  November 18th 2013 “four weeks after start date of procurement of raw materials”.

 

	 
	

(a)  Process development work of current route.

	 	  	

USD 40,000*

	

Completion date December 13th 2013.

	 
	 	 	 	 	 	 
	

  (b) Process development work of proposed route

	 	  	

USD 36,000*

	

Completion date December 13th 2013.

 

	 

 

DRL IRN – 100004118

 

  

22

  

 

	

4-   Completion of both Process optimization of selected route and analytical method validation (selected route).

 

	 	

Dr. Reddy’s

 

	

USD 24,000*

	 	

Commencement date - 16th December 2013.

 

Completion date - 19th January 2013

 

	 
	

5-    Receipt of Manufacturing License

	 	

Dr. Reddy’s

	  	 	

Within 4 weeks of commencing 4kg manufacturing campaign being no later than the 3rd February 2014.

 

	 
	

6-    4 Kg Campaign

a) Commencement of Manufacturing Campaign Commence 4kg PBT434 HBr Manufacture in plant under cGMP (as per agreed specifications)

 

b) Includes the contracting by Dr Reddy’s of AR Life Sciences to perform Step 4 (only) of a 7 step synthesis under cGMP conditions. Step 4 is a Raney Nickel hydrogenation. 

The optimised process for Step 4 has been developed by Dr. Reddy’s. AR Life Sciences will prepare Master Batch records for approval by Dr. Reddy’s and Prana. Post mutual approval, Dr. Reddy’s will oversee the batch execution at AR Life Sciences. The intermediate, CDCH4, will get tested and by AR Life Sciences in accordance with Dr. Reddy’s method of analysis

	 	

Dr. Reddy’s

	

USD 160,000*

 

Completion of 4 kg manufacturing of PBT 434 under agreed specifications and acceptance of COA.

 

Bonus payment of USD 20,000 if manufacturing of 4 kg PBT 434 is completed on or before the completion date.

	 	

Commencement date – 20th Jan 2014

 

Completion date – 31th March 2014

 

Timeline – Within 10 weeks from commence date.

 

Analysis and Dispatch – in the week of 1st April 2014

	 

 

DRL IRN – 100004118

 

  

23

  

 

	

 

c) Completion of 4 kg Manufacturing Campaign of PBT 434 under cGMP (as per agreed specifications), acceptance of Certificate of Analysis and executed batch records by Prana. Analysis and Dispatch completed.

 

d) Manufacturing Report of PBT 434

 

	 	  	

 

USD 20,000

 

Submission of manufacturing report and executed batch records.

	 	

 

Milestone payment upon completion

	 
	

 

 

e) Stability Study (36 months as per ICH guidelines

	 	  	  	 	

 

Payment of USD $9000 towards initial pull point of 1st month. Remaining payments as incremental payments (USD 1000) per timepoint over 36 months

 

	 

 

*Milestone payment on completion.

 

*Completion means completion of the laboratory work and finalization of the relevant Project Item in Development Report.

 

DRL IRN – 100004118

 

  

24

  

 

Appendix B

 

	
Sub Project 1: Sourcing of Raw Material (for process development of PBT434)

 

Raw materials for the project will be sourced and procured by Dr. Reddy’s

Deliverables:.

 

3-Chloro-2-nitrobenzoic acid with Dr. Reddy’s to begin process development work.

 

	
Sub Project 2: Submission of Manufacturing License

 

Prana to send Purchase Orders to Dr. Reddy’s for Manufacturing Licence for PBT434. Dr. Reddy’s to apply for Manufacturing License

 

Deliverables:

 

Manufacturing Licence for PBT434

 

	

Sub Project 3: Process Development of current and proposed route

 

a)     Process Development of current route

 

Deliverables

To repeat the synthesis of the current synthetic route from AMRI global as outlined in Scheme 1. Reaction of 3-chloro-2-nitrobenzoic acid with KOH to generate phenol 2 followed by reaction with sodium hypochlorite to provide 4,6-Dichloro-2-hydroxy-3-nitrobenzoic acid 3. Acid 3 is converted to the acid chloride followed by reaction with methylamine to generate amide 4. Reduction of amide 4 with Fe and ammonium chloride to afford Anthranilic acid derivative 5.

The coupling of intermediate 5 to N-Boc-N-Ethyl glycine 7 to provide the bis-amide 6. Cyclisation of bis-amide 6 to quinazolinone derivative 8 using methanesulfonic acid in acetic acid, in the presence of catalytic conc. H2SO4. Finally, conversion of quinazolinone derivative 8 to PBT434 with HBr. Yields will be comparable to those outlined in Scheme 1.

 

DRL IRN – 100004118

 

  

25

  

 

 

Scheme 1: Current Synthetic Route to PBT434

 

b)     Process Development of Alternate Route

 

Alternate route to PBT434:

 

Alternatively, PBT434 synthesis can be evaluated based on a five step process, as enclosed below. This approach is based on known methods using a three component and one-pot reaction starting from anthranilic acid, aniline and

N-Boc glycine in the presence of coupling reagent, triphenyl phosphite. (see examples in Bioorg. Med. Chem. 2008, 16, 2570-2578 & Bioorg. Med. Chem. Lett. 2007, 17, 3339-3343).

 

DRL IRN – 100004118

 

  

26

  

 

 

Scheme 2: Alternative Route to PBT434

 

Based on this, to adopt this approach for PBT434 synthesis, anthranilic acid derivative could be synthesized starting from 3-chloro-2-nitrobenzoic acid 1 in a three step process. Further, anthranilic acid derivative on one-pot reaction with side chain 7 in the presence of triphenyl phosphite in pyridine can generate the intermediate benzoxazinone derivative, which on reaction with methyl amine (reaction requires anhydrous conditions, methyl amine in toluene may require for the synthesis and in-house preparation would need to be considered) can generate the required quinazolinone derivative. Finally, reaction with HBr can undergo Boc deprotection and generate PBT434 as a HBr salt. 

This approach would be the novel route for synthesis of quinazolinone derivatives and require additional efforts in establishing the proposed one-pot chemistry and to familiarize the process.

 

Alternate route to N-Boc-N-ethylglycine (compound 7):

 

As per technical information, N-Boc-N-ethylglycine synthesis involved condensation of glyoxalic acid with ethyl amine and then reduction using Pd on carbon under hydrogenation conditions at 50 psi H2 pressure, and finally isolate product after Boc protection. Alternatively, compound 7 can also be synthesized from the methyl ester of glycine by reductive amination using acetaldehyde and sodium cyanoborohydride, followed by N-Boc protection and subsequent ester hydrolysis using LiOH (Bioorg. Med. Chem. Lett. 2009, 19, 2211-2214).

 

 

This approach is advantageous in avoiding the usage of palladium on carbon under hydrogenation conditions; however ester hydrolysis would be the additional stage in the process when compared with the current synthetic route

 

DRL IRN – 100004118

 

  

27

  

 

 

Another set of conditions to avoid hydrogenation is the use of chloroacetic acid and aqueous ethylamine solution to generate N-Ethylglycine in situ, followed by reaction with BOC anhydride to afford compound

7.

 

Deliverables for Sub-Project 3a) and 3b):

 

A comprehensive, detailed Familiarisation Report to be written up by Dr. Reddy’s on the current and alternate routes to PBT434 and submitted to Prana for review and approval. Without limitation, the report will contain detailed synthetic methods and operations to manufacture PBT434 via the existing route. The report will contain reaction yields and HPLC purities for each step. The purity profiles will be tabulated with relative retention times and their percentages clearly shown. The report will also contain work to manufacture PBT434 via the alternative route detailed in Scheme 2, shown above.

 

	  	
   Sub-Project 4: Completion of both Process optimisation of selected route and analytical method validation (selected route)

	 	  	  
	 	
a)

	
Method development for specification tests:

	 	
i)

	
HPLC or GC method for starting material, intermediates and in-process controls will be in placed as per requirement. Retentions of reagents used; as well possible by-products will be recorded for the process development

	 	
ii)

	
HPLC method provided in the section 5.1 of document number HRC0000808 would be used to determine the purity in final compound. The method would be evaluated for the proposed scheme and would be modified/developed as per the requirements of process.

	 	
iii)

	
Method will be validated for parameters like LOD, LOQ, Linearity, repeatability, ruggedness, solution stability, mobile phase stability, accuracy and specificity with forced degradation (using LC-DAD) in compliance with current ICH guidelines and in compliance with EMA and FDA requirements for Phase I development.

	 	
iv)

	
Residual solvents in final compound will be monitored by GC and/or GCHS techniques. Method will be developed to analyse the samples for all process solvents in compliance with current ICH limits and in compliance with EMA and FDA requirements for Phase I development

	 	
v)

	
Method validation will be performed with minimum parameters like LOD, LOQ, Linearity, repeatability, ruggedness, recovery, solution stability, specificity of all solvents in intended methods (in compliance with current ICH limits and in compliance with EMA and FDA requirements for Phase I development)

 

DRL IRN – 100004118

 

 

  

28

  

	 	  	  
	 	
vi)

	
Suitable method will be developed for quantification of Anion and Cation used in the process. Method would be verified for minimum parameters e.g. LOD, LOQ, Linearity, repeatability, ruggedness, recovery, solution stability (as applicable to the process).

	 	
vii)

	
An assay method for API will be developed and validated with minimum parameters including linearity, precision, and accuracy (in compliance with ICH, EMA and FDA requirements for Phase I development.

	 	
viii)

	
Reference markers for intermediates will be qualified for appropriate tests.

	 	
ix)

	
A reference standard of final API material will be qualified as per internal SOPs.

	 	  	  
	 	  	
Specification testing

	 	  	
The limits/range can be mutually agreed between two parties based on process capabilities and phase requirements. The key raw material, isolated intermediates and API material will be analysed for several tests as below.

 

	  	
S. No.

	  	
Tests

	  	
Specification

	  	
MOA ref. No.

	  	  	  	  	  	  	  	  
	  	
1.

	  	
Description

	  	
White to light brown color powder

	  	
AR&D-GTP-001

	  	  	  	  	  	  	  	  
	  	
2.

	  	
Identification by

	  	  	  	  
	  	  	  	  	  	  	  	  
	  	  	  	
a)     FT-IR

	  	
Shall matches to the standard

	  	
AR&D-GTP-003

	  	  	  	  	  	
 

	  	  
	 	 	 	 	 	The major peak in the sample	 	 
	  	  	  	
b)     HPLC

	  	
chromatogram should match

	  	
MF/CDCH7-002/00

	  	  	  	  	  	
with that of standard in assay

	  	  
	  	  	  	  	  	
preparation

	  	  
	  	  	  	  	  	  	  	  
	  	
3.

	  	
Water content by KF (%w/w)

	  	
Not more than 2.0

	  	
AR&D-GTP-005

	  	
4.

	  	
Residue on ignition (%w/w)

	  	
Not more than 0.30

	  	
AR&D-GTP-010

	  	
5.

	  	
Heavy metals (%)

	  	
Not more than 0.002

	  	
AR&D-GTP-011

	  	
6.

	  	
Assay by HPLC (on anhydrous and solvent free basis) (%w/w)

	  	
Between 97.0 and 103.0

	  	
MF/CDCH7-001/00

	  	
7.

	  	
Related substances by HPLC (%area)

	  	  	  	  
	  	  	  	  	  	  	  	  
	  	  	  	
a)     Any maximum impurity

	  	  	  	  
	  	  	  	  	  	  	  	  
	  	  	  	
b)     Total impurities

	  	
Not more than 0.25

	  	
MF/CDCH7-002/00

	  	  	  	  	  	  	  	  
	 	 	 	 	 	
Not more than 1.5

	 	 
	  	  	  	  	  	 	  	  

 

DRL IRN – 100004118

 

 

  

29

  

	 	
8.

	 	
Residual solvents by GC-HS (in ppm)

	 	  	 	  
	 	 	 	 	 	 	 	 
	 	  	 	
i)      Ethyl acetate

	 	  	 	  
	 	 	 	 	 	 	 	 
	 	  	 	
ii)     Toluene

	 	
Not more than 5000

	 	  
	 	 	 	 	 	 	 	 
	 	  	 	
iii)    Methanol

	 	
Not more than 890

	 	
MF/CDCH7-003/00

	 	 	 	 	 	 	 	 
	 	  	 	
iv)    Hexanes

	 	
Not more than 3000

	 	  
	 	 	 	 	 	 	 	 
	 	  	 	
v)     Tetrahydrofuran

	 	
Not more than 290

	 	  
	 	 	 	 	 	 	 	 
	 	  	 	
 

	 	
Not more than 720

	 	  
	 	 	 	 	 	 	 	 

 

	 	  	
* Solvents are considered from stage 4 onwards

	 	  	  
	 	  	
Deliverables for Sub-project 4 (a)

	 	  	  
	 	
●

	
Develop and document analytical methods for key starting materials and intermediates for the manufacture of PBT434. Included are HPLC, Loss on Drying, GC and Infrared Spectroscopy.

	 	
●

	
Set specifications and document for each intermediate according to the developed analytical methods that have to be agreed and approved by Prana.

	 	
●

	
Dr. Reddy’s to write a comprehensive validation report for the assay methods and submit to Prana for review and approval.

	 	
●

	
Dr. Reddy’s to develop and document a Related Substance Method for PBT434

	 	
●

	
Dr. Reddy’s to develop and document a GC Methods to determine solvent levels for stage 4 intermediates onwards.

	 	
●

	
Dr. Reddy’s to develop and document analytical methods to determine the final purity of PBT434

	 	
●

	
Reference standard of PBT434 20 gm to be qualified according to Dr. Reddy’s SOP’s and the standard is to be reviewed and approved by Prana in writing. Reference standard of PBT 434 will be taken from Lab assurance batches.

	 	 	 
	 	
b)

	
Completion of both Process optimisation of selected route

 

 Stage-1:

As per the given process shown in Scheme 1, stage-1 involves 3-Chloro-2-nitrobenzoic acid 1 on treatment with aq KOH (14 eq) to generate the corresponding phenolic derivative 2 at reflux temperature. After completion of reaction, extract product at pH 2 with ethyl acetate and then product isolation by adding hexane.

 

Process optimization plan:

	 	  	  
	 	
●

	
The requirement of excess usage of KOH (14 eq) and lot wise addition will be evaluated.

	 	
●

	
Product isolation at pH 2 directly from aqueous mixture will be studied, which can avoid ethyl acetate extraction and product isolation from ethyl acetate-hexane mixture.

	 	
●

	
Exploring the possibility of direct subjection of stage-1 wet cake to chlorination with aq NaOCl (in-situ process).

 

DRL IRN – 100004118

 

 

  

30

  

Stage-2:

 

Stage-2 involves aromatic chlorination using aqueous sodium hypochlorite solution at 80°C. After completion of reaction, extract product at pH 2 with ethyl acetate followed by concentration of organic layer and then finally product isolation by triturating with hexane. 

 

Process optimization plan:

 

	●	As per the technical information, stage-1  purity is more than 99%, which is the input for chlorination. After Chlorination, stage-2 product purity is ~90%.
	●	To improve the purity, purification of stage-2 will be explored.
	●	Product isolation at pH 2 directly from aqueous mixture will be evaluated, which can avoid ethyl acetate extraction, concentration and product isolation by triturating with hexane.

 

Stage-3:

 

Stage-3 involves amide formation by converting acid to acid chloride using thionyl chloride followed by reaction with methyl amine. After completion of reaction, extract product at pH 2 with ethyl acetate followed by concentration of organic layer and then finally product isolation by triturating with hexane.

 

Process optimization plan:

 

	●	Studying acid chloride formation in the presence of a solvent, i.e. in toluene media
	●	Complete removal of thionyl chloride from the reaction mixture after acid chloride formation is necessary for amide formation.
	●	Acid chloride synthesis in toluene will be advantageous in complete removal of SOCl2 from reaction mixture by co-distillation.
	●	As per scale up information from Prana, one of the batches is reported for low product purity (79% against the trend of ~94%) and yields varied from 86-99%.
	●	Since aq methyl amine is used in the process, re-generation of acid during the amide formation may be possible. Though, aromatic acid chlorides are stable to some extent, reaction conditions need to be established for robustness.

 

Stage-4:

 

Process involves synthesis of key intermediate 9 by reduction of nitro functionality using iron powder in the presence of ammonium chloride.

 

Process optimization plan:

 

	●	Based on our experience in reduction of aromatic nitro group, Raney Ni would be the preferred reagent.
	●	Alternate reaction conditions will be explored using Raney Ni under hydrogenation conditions and compare impurity profile and yield.

 

Stage-5:

 

Process involves compound 9 on reaction with side chain 7 (generated by condensing glyoxalic acid and ethyl amine followed by reduction under hydrogenation conditions using Pd/C and finally Boc protection) in the presence of CDI and triethyl amine at room temperature to generate compound 10. After completion of reaction, extract product with ethyl acetate and concentrate. Finally, isolate product from ethyl acetate.

 

DRL IRN – 100004118

 

 

  

31

  

 

Process optimization plan:

 

	●	Establish reaction conditions and product isolation process for compound 10 as per the given process.

 

Stage-6:

 

Stage-6 is the quinazolinone ring formation from compound 10 using acetic acid in the presence of H2SO4 at 120°C and finally isolate compound 11 as methane sulfonic acid salt.

 

Process optimization plan:

 

	●	We will try to replace Ethanol with isopropanol in the process.
	●	As per tech information, yields from the scale up batches varied from 36% to 52% with approximate product purity ~97%.
	●	Product purification trials will be explored to improve the purity.

 

Stage-7:

 

PBT434 is synthesized by treating compound 11 with aq HBr at room temperature. 

 

Process optimization plan:

 

	●	We will try to replace Ethanol with isopropanol in the process.
	●	Specification for PBT434 is purity NLT 99% with single maximum impurity NMT 0.15%.
	●	One of batch from tech pack shows impurity at a level of 0.37% with product purity 99.49%
	●	Product purification trials will be explored to improve the purity.

 

Synthesis of N-Boc-N-ethylglycine (compound 7):

Process involves condensation of glyoxalic acid with ethyl amine at 40 °C followed by reduction under hydrogenation conditions using Pd/C at 50 psi hydrogen pressure. After completion of reaction, filter the catalyst and then finally subject for Boc protection. After completion of reaction wash reaction mixture with MTBE and adjust aqueous layer pH to 2-3 with citric acid. Extract aqueous layer using ethyl acetate and concentrate under reduced pressure to generate compound 7.

 

Process optimization plan:

 

Establish reaction conditions for compound 7 as per the given process.

 

Deliverables for Sub-Project 4b

 

Dr. Reddys will write a comprehensive Process Development Report on the Selected Route. Without limitation, the report will contain reaction schemes to manufacture PBT434. There will be a detailed experimental write-up with HPLC, IR, proton and carbon NMR for each intermediate. Submit to Prana for review and written approval.

 

DRL IRN – 100004118

 

 

  

32

  

	
Sub-Project 5: Receipt of Manufacturing Licence

	  	  	
Deliverables for Sub-Project 5

	  	  	
Dr. Reddy’s to receive a manufacturing licence for PBT434 no later than February 3, 2014

	
Sub-Project 6: GMP Manufacture of 4kg PBT434 HBr

	  	
a)

	
                    Commence 4kg PBT434 HBr Manufacture in plant under cGMP by the 20th of January, 2014

	  	  	
(i) Dr. Reddy’s will manufacture 4kg of PBT434 drug substance according to the applicable regulatory and statutory requirements of current Good Manufacturing Practices (GMP) (US 21 CFR parts 210 and 211 and ICH Q7) in the following scenario:

	  	  	
(ii) Dr Reddy’s will strictly adhere to all the decisions agreed and during Process Development (Sub-project 3) with regards to the type and material of construction of the equipment to be used in the manufacture, the quality and suppliers of reagents and solvents, the type of reactors to be used, the timing of use of the Cleanroom. Any changes in equipment, master batch records, specifications, methods or any other aspect of the manufacture from the previous 2010 manufacture that are not explicitly justified in the Familiarisation report (sub-project 3) will need written approval by Prana.

	  	  	  
	  	  	
Deliverables for Sub-project 6a):

	  	  	  
	  	●	
Technology transfer for Stage 1 to be completed by Dr. Reddy’s by the 20th of January, 2014

	  	●	
Master batch records for Stage 1 to be approved and signed off in writing by Prana

	  	●	
Reactors assigned to Stage 1 to be washed and ready for use in PBT2 manufacture.

	  	●	
All personnel assigned to PBT434 manufacture to be identified in writing and available.

	  	●	
3-Chloro-2-nitrobenzoic acid and all reagents and solvents to be used in Stage 1 to be received and released for use

	  	●	
Stage 1 to be initiated in the plant by no later than January 20, 2014

	  	  	  
	  	
b)

	
                    Completion of 4kg Manufacturing Campaign of PBT434 HBr under cGMP (as per agreed specifications), acceptance of Certificate of Analysis and executed batch records by Prana.

	  	  	
i) The manufacture will proceed as per the agreed master batch records. Prana will be informed of all deviations, however minor, and those will be dealt with as per the Quality Agreement

	  	  	
ii) All results will be communicated to Prana immediately. Any result that raises questions will be communicated to Prana ahead of any internal investigation so Prana can be take part in resolving issues.

	  	  	
iii) The existing analytical methods as well as the refined analytical methods as per Sub Project 3, will be used to release intermediates and final materials. All intermediates and final material will meet the specifications agreed in writing with Prana prior to manufacture

 

DRL IRN – 100004118

 

 

  

33

  

 

	  	  	
Deliverables for Sub-project 6c):

	  	  	  
	  	●	
Technology transfer for Stage 2 onwards to be completed by Dr. Reddy’s

	  	●	
Master batch records for Stage 2 onwards to be approved and signed off in writing by Prana

	  	●	
Release data for all intermediates and final material to be received and approved in writing by Prana

	  	●	
Certificate of Analysis, Certificate of GMP compliance and other release documents to be received by Prana and approved in writing.

	  	●	
Master Batch records for all stages to be provided to Prana, reviewed and any amendments and comments promptly attended to by Dr Reddy’s.

	  	●	
All information relevant to the manufacture and required for regulatory purposes(including FDA IND) to be provided to Prana, including but not limited to, the description of the manufacturing process, batch traceability, Certificates of Analysis of all reagents and solvents. In addition, Dr Reddy’s should record all suggestions for improvement in future campaigns or areas in need of further investigation. Such information should be provided in a Manufacturing Campaign Report.

	  	  	  
	  	
c)

	
Strategic Business Partner- Step 4 Raney Nickel Hydrogenation

	  	  	  
	  	  	
Includes the use of AR Life Sciences to perform Stage 4 only of a 7 stage synthesis under cGMP conditions. Stage 4 is a Raney Nickel hydrogenation.

	  	  	
The optimised process for Stage 4 has been developed by Dr. Reddy’s. AR Life Sciences will prepare Master Batch records for approval by Dr. Reddy’s and Prana. Post mutual approval, Dr. Reddy’s will oversee the batch execution at AR Life Sciences. Finally, the intermediate, CDCH4, will get tested and by AR Life Sciences in accordance with Dr. Reddy’s method of analysis.

	  	  	  
	  	  	
Deliverables

	  	●	
AR Life Sciences to write batch records for Stage 4 that require approval from both Dr. Reddy’s and Prana.

	  	●	
AR Life Sciences to write methods of analyses and in-process controls for Step 4 that require approval from both Dr. Reddy’s and Prana.

	  	●	
Stage 4 Intermediate released by Dr. Reddy’s according to methods of analyses from AR Life Sciences.

	  	  	  
	  	
d)

	
                    Stability Study (36 Months as per ICH guideline)

	  	  	
A stability study, conducted according to the according to the ICH guideline “Q1A(R2) Stability Testing of New Drug Substances and Products”, will commence immediately after manufacture of 4 Kg GMP PBT434 API. The existing analytical methods as well as the refined analytical methods as per Sub Project 4a, will be used for the stability studies (6 month accelerated study and 36 months long term study). The accelerated study will have following data points - 0, 1, 2, 3, and 6 months. The long term study will have the following data points - 0, 1, 3, 6, 9, 12, 18, 24 and 36 months.

 

DRL IRN – 100004118

 

  

34

  

 

	  	  	
Deliverables for each timepoint:

	  	  	  
	  	●	
Dr. Reddy’s to write a QA-checked stability report to be received by Prana within 2 weeks of pulling the samples.

	  	  	
                    Raw data from each timepoint to be submitted to Prana.

 

DRL IRN – 100004118

 

 

35exhibit_4-39.htm

Exhibit 4.39

 

AMENDMENT

 

to the Clinical Trial Agreement between

Prana Biotechnology Limited

and

The University of Rochester

 

WHEREAS, The University of Rochester (“Institution”) and Prana Biotechnology Limited (“Sponsor”) have entered into a Clinical Trial Agreement dated October 7, 2011 relating to clinical trial services with regard to the product PBT2 (“Agreement”), and

 

WHEREAS, the Protocol for the Study has been amended February 3, 2012 and thus changes are needed to the Budget, and the Institution and Sponsor have agreed upon a revised Budget,

 

NOW, THEREFORE, the parties hereby agree to amend the Agreement effective February 17, 2012, by replacing Attachment A to the Agreement with the amended Protocol attached hereto as Attachment Al, and also by replacing Attachment B to the Agreement with the revised Budget attached hereto as Attachment B1.

 

Except as provided herein, all terms and conditions of the Agreement remain unchanged and in full force.

 

	
PRANA BIOTECHNOLOGY LIMITED

	  	
UNIVERSITY OF ROCHESTER

	 
	  	  	  	  	  	 
	
BY:

	           	  	
BY:

	  	 
	
Name:

	DIANNE ANGUS	  	  	
Cheryl K. Williams

	 
	
Title:

	CHIEF OPERATING OFFICER	  	  	
Assistant Director

	 
	  	  	  	  	
Office of Research & Project Administration

	 
	  	  	  	  	  	 
	
DATE: 

	February 20, 2012	  	
DATE:  

	  	 

 

  

  

  

ATTACHMENT A1 

 

AMENDED PROTOCOL

 

  

  

  

 

ATTACHMENT B1 

 

REVISED BUDGET

 

  

  

  

 

AMENDMENT 2

 

to the Clinical Trial Agreement between

Prana Biotechnology Limited

and

The University of Rochester

 

WHEREAS, The University of Rochester (“Institution”) and Prana Biotechnology Limited (“Sponsor”) have entered into a Clinical Trial Agreement dated October 7, 2011, as amended February 17, 2012, relating to clinical trial services with regard to the product PBT2 (“Agreement”), and

 

WHEREAS, Institution and Sponsor have agreed upon a revised Budget,

 

NOW, THEREFORE, the parties hereby agree to amend the Agreement effective May, 2012, by replacing Attachment B1 to the Agreement with the revised Budget attached hereto as Attachment B2.

 

Except as provided herein, all terms and conditions of the Agreement remain unchanged and in full force.

	  	  	  	  	  	  
	
PRANA BIOTECHNOLOGY LIMITED

	  	
UNIVERSITY OF ROCHESTER

	  
	  	  	  	  	  	  
	
BY:

	

	  	
BY:

	

	  
	
Name:

	DIANNE ANGUS	  	  	
Cheryl K. Williams

	  
	
Title:

	
CHIEF OPERATING OFFICER.

	  	  	
Assistant Director

	  
	  	  	  	  	
Office of Research & Project Administration

	  
	  	  	  	  	  	  
	
DATE:

	
28th September 2012.

	  	
DATE:

	
10/3/2012

	  

 

  

  

  

 

Amendment 2 to MSA

- Budget V26, 1150112.

 

University of Rochester

Encompassing the Huntington Study Group

Clinical Trials Coordination Center (CTCC)

Biostatistics Department

265 Crittenden Blvd.

Rochester, NY 14642

585-275-7311

 

Prana

Project Name Reach2HD

Confidential

 

Please note: This budget proposal is based on the Scope of Work and Protocol (version #2, February 3, 2012) agreed on February 3, 2012. Should the Protocol or SOW change, the HSG & CTCC will require a revised budget, adjusted SOW, protocol and Agreement with the potential for additional funding to complete the outlined tasks. This budget proposal is valid to June 30, 2012.

 

  

  

  

 

	  	  	  	  	  	 
	  	
PROJECT TITLE:

	  	
Reach2HD

	  	 
	  	  	  	  	  	 
	  	
Protocol Title:

	  	
PBT2-203 Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center, Phase lia Study of two doses of PBT2.

	 
	  	  	  	  	  	 
	  	
Principal Investigator:

	  	
Kayson, UR

Prime Institution: UR

Subcontract to JHU, Dorsey

Subcontracts to 20 Sites

	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	  	  	  	  	  	 
	  	
Timeline:

	
Planning:

Enrollment:

Implementation:

Close Out:

	
6 Months

9 Months

6 Months

4 Months

	
01 October 2011 to 31 March 2012

31 March 2012 to 31 December 2012

01 January 2013 to 30 June 2013

01 July 2013 to 31 October 2013

	 
	  	  	  	  	  	 
	  	
# of Sites

	  	
20

	
Approx 15 USA; Approx 5 Aust

	 
	  	  	  	  	  	 
	  	
# of Subjects

	  	
100 Randomized

	  	 
	  	  	  	  	  	 

	  	
Planning Phase

 

 01 October 2011 to

 31 March 2012

	  	  	  	  
	  	 	
Enrollment Phase

 

 31 March 2012 to

 31 December 2012

	  	  	  
	  	  	  	
LPI Phase

 

 01 January 2013 to

 30 June 2013

	  	  
	  	  	  	  	
Close Out Phase

 

 01 July 2013 to 31

 October 2013

	  

	
 Top Level Summary

	
Planning

	
Enrollment

	
Implementation

	
Close Out Phase

	  	
Total

	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	
-   

	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	
-    

	  
	  	  	  	  	  	  	  	  	  
	  	
CTCC Budget

	
221,587   

	
580,374   

	
347,240   

	
219,478   

	  	
1,368,679    

	  
	  	  	  	  	  	  	  	  	  
	  	
Other Budget

	
20,000   

	
40,000   

	
70,000   

	
30,000   

	  	
160,000    

	  
	  	  	  	  	  	  	  	  	  
	  	
Total UR Direct Costs

	
241,587   

	
620,374   

	
417,240   

	
249,478   

	  	
1,528,679    

	  
	  	  	  	  	  	  	  	  	  
	 	 	 	 	 	 	 	 	 
	  	
Contract/Consortium (Sites, JHU)

	
89,637   

	
1,222,081   

	
971,351   

	
283,646   

	
#

	
2,566,715    

	  
	  	  	  	  	  	  	  	  	  
	  	
Total Direct Costs

	
331,224   

	
1,842,456   

	
1,383,590   

	
533,123   

	
#

	
4,095,393    

	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	  	
Facilities and Administrative Costs

	
93,305   

	
392,131   

	
146,034   

	
87,317   

	
#

	
718,787    

	  
	  	  	  	  	  	  	  	  	  
	 	 	 	 	 	 	 	 	 
	  	
Total Costs

	
424,530   

	
2,234,587   

	
1,534,624   

	
620,440   

	
#

	
4,814,181    

	  
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	 	 	 	 	 	 	 	 	 
	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  

	  	  	  
	  	
Pass Thru Costs Invoiced Directly to Sponsor outside of the payment schedule for Trial:

	  	  
	  	  	
Source Document Worksheets printing and distribution -- to be a pass thru cost

	  	  	
Operations Manual Printing and Distribution -- to be a pass thru cost

	  	  	
Drug Instruction Card printing and distribution -- to be a pass thru cost

	  	  	
Travel and Conference costs -- to be a pass thru cost (include Orientation Meeting)

	  	  	
IRB fees -- to be a pass thru cost

	  	  	
Site Audit Fees (applicable for a ‘not for cause’ audit) -- to be a pass thru cost

	  	  	
Site Pharmacy Start up fees as needed ($1,000 to $2,500 based upon actual needs at enrolling sites) -- to be a pass thru cost

	  	  	
Screen Failures to be paid based upon assessments completed per subject, to be paid at the end of enrollment -- as a pass thru cost

	  	  	
Subject Travel to attend study visits (above stipend for instances of hardship and pre-approved by sponsor) -- as a pass thru cost

	  	  	
Unscheduled Visits for enrolled subjects to be invoiced to Sponsor as incurred

	  	  	  
	  	  	
Subcontracts to MGH (Hersch and Rosas) and Melborne, Australia (Stout) to be held by Sponsor

	  	  	
Steering Committee and Safety Monitoring Committee Fees to be paid directly to committee members by Sponsor

	  	  	
Monitoring visits to Australian sites to be the direct responsibility of Sponsor

	  	  	
Central Laboratory analysis activities -- paid directly by Sponsor

	  	  	
Central ECG analysis activities -- paid directly by Sponsor

	  	  	
Copyright Fees -- paid directly by Sponsor

	  	  	  
	  	  	
Any material changes to the SOW will necessitate a modification to the budget and a contract amendment.

	  	  	
Example of SOW changes include, but not limited to: Protocol Amendments, Adding Sites, Interim Analyses, Ancillary Studies.

 

  

  

  

 

	
 JHU Subcontact

	 	
Planning

	  	
Enrollment

	  	
LPI

	  	
Close Out

	  
	  	  	  	  	  	  	  	  	  
	
 Employement Costs

	
66,398    

	  	
107,894    

	  	
70,341    

	  	
61,008    

	  
	
 Consultant POs

	
-    

	    	
-    

	  	
-    

	  	
-    

	  
	
 Computing Costs

	
-    

	  	
-    

	  	
-    

	  	-   	  
	
 Equipment Purchases

	
-    

	  	
-    

	  	-   	  	-   	  
	
 Travel Costs

	
-    

	  	
-    

	  	
-    

	  	
-    

	  
	
 Operating Costs (T, P/C, P, O)

	
-    

	  	
-    

	  	
-    

	  	
-    

	  
	
 Other Costs

	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
 Facilities and Administrative Costs

	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
	
 Total Direct Costs

	
66,398    

	  	
107,894    

	  	
70,341    

	  	
61,008    

	  

	  	  	  	  	  
	  	
Planning Phase

  01 October 2011 to 31 March 2012

	
Enrollment Phase

  31 March 2012 to 31 December 2012

	
LPI Phase

  01 January 2013 to 30 June 2013

	
Close Out Phase

  01 July 2013 to 31 October 2013

	  	
6 months

	
9 months

	
6 months

	
4 months

	 	  	  	  	  	  	  	  	  	  
	
EMPLOYMENT COSTS

	  	  	  	  	  	  	  	  	  
	
% of Effort Data

	  	
Planning

	  	
Enrollment

	  	
LPI

	  	
Close Out

	  
	  	  	
% Effort

	
Person

Months

	
% Effort

	
Person

Months

	
% Effort

	
Person

Months

	
% Effort

	
Person

Months

	
Dorsey, Ray

	
Co Investigator

	
30%  

	
3.60    

	
30%  

	
3.60    

	
30%  

	
3.60    

	
30%  

	
3.60     

	
TBD

	
Research Asst

	
10%  

	
1.20    

	
10%  

	
1.20    

	
10%  

	
1.20    

	
30%  

	
3.60     

	
TBD

	
Asst Professor

	
15%  

	
1.80    

	
15%  

	
1.80    

	
15%  

	
1.80    

	
15%  

	
1.80     

	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  
	
Total Employment Costs

	  	
66,398  

	  	
107,894  

	  	
70,341  

	  	
61,008  

	  
	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  
	
Facilities and Administrative Costs to JHU

	
23,239  

	  	
37,763  

	  	
24,620  

	  	
21,353  

	  
	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  
	
JHU Total Cost

	  	
89,637  

	  	
145,656  

	  	
94,961  

	  	
82,361  

	  

 

  

  

  

 

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	
BIOSTATS

	 	  	  	
Planning

	  	
Enrollment

	  	
LPI

	  	
Close Out

	  
	
Employment Costs

	  	  	  -	  	  	-	  	  	-	  	  	-	  
	
Consultant POs

	  	  	-	  	  	-	  	  	-	  	  	-	  
	
Computing Costs

	  	  	-	  	  	-	  	  	-	  	  	-	  
	
Equipment Purchases

	  	  	-	  	  	-	  	  	-	  	  	-	  
	
Travel Costs

	  	  	-	  	  	-	  	  	-	  	  	-	  
	
Operating Costs (T, P/C, P, O)

	  	  	-	  	  	-	  	  	-	  	  	-	  
	
Other Costs

	  	  	
20,000

	  	  	
40,000

	  	  	
70,000

	  	  	
30,000

	  
	
Other Costs

	  	  	  	  	  	  	  	  	  	  	  	  	  
	
Other Costs

	  	  	  	  	  	  	  	  	  	  	  	  	  
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
Total Direct Costs

	  	  	
20,000

	  	  	
40,000

	  	  	
70,000

	  	  	
30,000

	  

 

  

  

  

 

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	
One Time Start up Fee

	  	  	
$

	
3,500

	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	
Ophthalmologic Visit Costs:

	
Exam

	  	
$

	
460

	  	  	  	  	
$

	
180

	  	
$

	
180

	  
	  	
Color Vision

	  	
$

	
186

	  	  	  	  	
$

	
186

	  	
$

	
186

	  
	  	
OCT

	  	
$

	
364

	  	  	  	  	
$

	
364

	  	
$

	
354

	  
	  	
Confrontation VF

	  	
$

	
140

	  	  	  	  	
 

	 	  	
$

	
140

	  
	  	
Ophthalmoscopy

	  	
$

	
70

	  	  	  	  	
$

	
70

	  	
$

	
70

	  
	  	
Fundus Photos

	  	
$

	
165

	  	  	  	  	
 

	 	  	
$

	
165

	  
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	  	  	  	
$

	
1,385

	  	
$

	
-

	  	
$

	
800

	  	
$

	
1,105

	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	
Visually Evoked Response****

	
The VER will occur for approximately 50% of the subjects enrolled; will be paid for as occurring at $425 per VER includes the assessment and reading

	  	
$

	
425

	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	
Total Per Subject Fee for Subjects not receiving the Visual Evoked Response Assessment Per Subject Fee composed of Screening Visit thru Week 28 follow Up Visit

	  	
$

	
20,129

	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	
Total Per Subject Fee for Subjects receiving the Visual Evoked Response Assessment

	  	
$

	
21,404

	  

 

	
SNAP Assessment

	
Cost to be determined

	 

 

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	
Budget Details:

	  	
   Planning Phase

	  	
Enrollment Phase

	  	
  LPI Phase

	  	  	  
	  	  	  	
100

	  	
01 October 2011 to 31 March 2012

	  	
31 March 2012 to 31

	  	
01 January 2013 to 30 June 2013

	  	  	  	  
	  	  	
$

	
20,129

	  	  	
6 months

	  	  	
9 months

	  	  	
6 months

	  	  	  	  
	  	  	
$

	
2,012,850

	  	  	  	  	  	  	  	  	  	  	  	  	  
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	  	  	  	
0

	
%

	  	
0

	  	  	  	  	  	  	  	  	  	  
	  	  	  	
50

	
%

	  	  	  	
$

	
1,006,425

	  	  	  	  	  	  	  
	  	  	  	
40

	
%

	  	  	  	  	  	  	
$

	
805,140

	  	  	  	  
	  	  	  	
10

	
%

	  	  	  	  	  	  	  	  	  	  	
201285

	  
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

  

  

  

 

	 	 	 	 	 	 	 	 	 
	  	
PROJECT TITLE:

	  	Reach2HD	  	  	 	  
	 	 	 	 	 	 	 	 	 
	  	
Protocol Title:

	  	PBT2-203 Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center, Phase lia Study of two doses of PBT2.	  	 	  
	 	 	 	 	 	 	 	 	 
	  	
Principal Investigator:

	  	
Kayson, UR

	  	  	 	  
	  	  	  	
Prime Institution: UR

	  	  	 	  
	  	  	  	
Subcontract to JHU, Dorsey

	  	  	 	  
	  	  	  	
Subcontracts to 20 Sites

	  	  	 	  
	  	  	  	  	  	  	  	 	  
	  	
Timeline:

	
Planning:

	
6 Months

	           01 October 2011 to 31 March 2012	  	  	 	  
	  	  	
Enrollment:

	
9 Months

	           31 March 2012 to 31 December 2012	  	  	 	  
	  	  	
Implementations:  

	
6 Months

	           01 January 2013 to 30 June 2013	  	  	 	  
	  	  	
Close Out:

	
4 Months

	           01 July 2013 to 31 October 2013	  	  	 	  
	  	  	  	  	  	  	  	 	  
	  	
# of Sites

	  	
20

	           Approx 15 USA; Approx 5 Aust	
 

	 	  
	 	 	 	 	 	 	 	 
	  	
# of Subjects

	  	
100 Randomized

	  	  	 	  
	  	  	  	  	  	  	  	 	  
	 	 	 	 	 	 	 	 	 
	  	  	
Total Budget

	  	  	  	
4,814,181

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	
Less: Budget associated with Site Subcontract Payments

	
(2,154,100)

	 	  
	  	  	
and associated indirect costs

	
(175,000)

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	
Budget Subject to Milestone Payment Scheme

	
2,485,081

	 	  
	  	  	  	  	  	  	  	 	  
	 	 	 	 	 	 	 	 
	  	  	
Payment Scheme:

	  	  	  	 	  
	  	  	  	  	  	  	  	 	
Billed and Rec’d

	  	  	  	  	  	  	  	 	  
	  	  	
The amount due to the University of Roachester will be invoiced according to the following Milestone driven scheme:

	  	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	
Completion of Fully Executed Contract

	
10%

	
248,508

	 	
390,445  

	  	  	  	  	  	  	  	 	  
	  	  	  	
IND for Protocol opened

	
10%

	
248,508

	 	
390,445  

	  	  	  	  	  	  	  	 	  
	  	  	  	
Receipt of initial IRB approval of protocol

	
5%

	
124,254

	 	
-   

	  	  	  	  	  	  	  	 	  
	  	  	  	
Initial Enrollment

	
10%

	
248,508

	 	
90,913  

	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Subtotal of cashflow through initial enrollment

	  	
869,778

	 	
871,803  

	  	  	  	  	  	  	  	 	  
	  	  	  	
Quarterly Payment During Enrollment and Implementation Phases

	  	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Month 3 of Enrollment

	
9%

	
223,657

	 	
221,633  

	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Month 6 of Enrollment

	
9%

	
223,657

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Month 9 of Enrollment

	
9%

	
223,657

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Month 3 of Implementation

	
9%

	
223,657

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Month 6 of Implementation

	
9%

	
223,657

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Subtotal of cashflow thru Implementation

	  	
1,118,286

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	
Payment upon completion of Subject Enrollment

	  	  	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Database Lock

	
10%

	
248,508

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Top Line Results

	
5%

	
124,254

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
CSR

	
5%

	
124,254

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	
Subtotal of final payments

	  	
497,016

	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	  	  	  	  	 	  
	  	  	  	
Total of all payments not subject to subcontract

	  	
2,485,081

	 	  
	  	  	  	  	  	  	  	 	  
	  	
Site Payment Scheme:

Invoices will be forwarded to sponsor on a calendar quarter for basis for costs incurred in paying sites for completed visits.

Not more than $2,329,100 will be invoiced to sponsor, invoices will only include the costs of fully completed and documented visits.

The following is an estimate of the invoice amounts:

	 	  

	 	  	  	  	  	  
	 	
Quarter ended June 30, 2012

	  	
$

	
116,455

	  
	 	
Quarter Ended September 30, 2012

	  	
$

	
582,275

	  
	 	
Quarter Ended December 31, 2012

	  	
$

	
465,820

	  
	 	
Quarter Ended January 31, 2013

	  	
$

	
465,820

	  
	 	
Quarter Ended March 31, 2013

	  	
$

	
349,365

	  
	 	
Quarter Ended June 30, 2013

	  	
$

	
349,365

	  
	 	 	 	 	 	 
	 	
Total

	  	
$

	
2,329,100

	  
	 	 	 	 	 	 

	  	  	  
	  	

NOTE: If the FDA delays the implementation of the study according to the agreed timeline, the parties have the right to re-negotiate the milestones according to a agreed, revised timeline.

 

(a) Should the above timeline for planning, Enrollment Implementation and/or Close out exceed the budgeted period for reasons outside the control of the Clinical Trials Coordination Center (CTCC), the CTCC will request that the Scope of Work be revisited and the budget be revised (if necessary) to allow for an expanded Planning, Enrollment, Implementation and/or Close out timeframe and associated additional costs. In good faith, Prana will decide if  the proposed budget or timeframe changes can be accommodated by Prana. In any event, the CTCC will not be under an obligation to continue the study without the required additional funds to cover an extended budget period and Prana will not obliged to continue the Study outside the budgeted period.

 

(b) If the above timeline for Planning, Enrolment, Implementation and Close out exceed the budgeted period for reasons within the control of the Clinical Trials Coordination Center (CTCC), Prana may withhold payments and/or require the CTCC to undertake activities to restore as far as possible the Study to the Initial Timeline at CTCC’s cost. If a delay in recruitment timeline is for reason of particular obligations on patients as prescribed by the Protocol, and the impact of those Protocol obligations cannot otherwise be resolved by the parties Project Team, the delay will not be deemed an event within the control of the CTCC.

 

(c) If the above timeline for Planning, Enrollment, Implementation and Close Out is less than the budgeted period, the Scope of Work will be revisited by the parties and the budget be revised (if necessary) to adjust for the reduced timeframe and additional costs. For each month of reduced timeline of the Study, Prana will pay a pro-rata amount of the above Quarterly Payments to the CTCC as a bonus for earlier Study completion.

 

	  

 

  

  

  

 

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	
Analysis of monitoring Activities

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	
Budget Components

	  	
Planning

	  	  	  	
Enrollment

	  	  	  	
Implementation LP1 Duration

	  	
Close out

	  	
Total

	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	
Effort

	  	  	
Site Monitor Employee

	  	  	
0

	
%

	  	
-

	  	  	
80

	
%

	  	  	  	  	
80%

	
           

	  	
0

	
%

	  	  	  
	  	
Fees

	  	  	
Independent Monitor/Contractor Fees

	  	  	  	  	  	  	  	
$

	
43,200

	  	  	  	  	
$

	
21,600   

	  	  	  	  	
$

	
64,800

	  
	  	
Travel

	  	  	
Site Monitor Travel Costs

	  	  	  	  	  	  	  	
$

	
100,800

	  	  	  	  	
$

	
36,000   

	  	
$

	
7,200

	  	
$

	
144,000

	  
	  	
TOTAL

	  	  	  	  	  	  	  	  	  	  	
$

	
144,000

	  	  	  	  	
$

	
57,600   

	  	
$

	
7,200

	  	
$

	
208,800

	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	
Based upon the budgeted effort, independent contractor costs and the associated travel costs, a total of 120 to 123 site monitor visits are budgeted. The details of these visits is set out below. Approximately 120 visits will provide 8 visits per site over the enrollment and LPI phase.

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	
Planning phase

6 months

	  	
Enrollment Phase

9 months

	  	
LPI Phase

6 months

	  	
Close Out Phase

4 months

	  
	
Effort Analysis

	  	
Monitor Effort----------->

	  	  	
0

	
%

	  	
80

	
%

	  	
80

	
%

	  	
0

	
%

	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	
Independent Contractor Hourly Fees ---->

	  	
$

	-	  	
$

	
43,200

	  	
$

	
21,600

	  	$	  -	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	
Effort

	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	
80% of one FTE indicates 32 hours per work week for a total of 2080 hours over the 15 month implementation period.

	  
	  	  	
2080 total available hours divided by 24 hours per monitor trip yields 87 site visits.

	  
	  	  	
Therefore, in the 15 months there are enough hours budgeted for approximately 87 visits to sites.

	  
	  	  	  	  
	  	  	
Independent Contractor

	  
	  	  	
A total of 9 visits to four sites are budgeted to be handled by up to three independent contractors. In aggregate, 36 visits are budgeted with each visit planned to be 24 hours at a rate of $75 per hour.   The computation is 36 visits multiplied by 24 hours per visit multiplied by $75 per hour.

	  
	  	  	
36 visits x 24 hours per visit x $75 per hour results in $64,800.

	  
	  	  	  	  
	  	  	
In total approximately 123 site monitor visits are budgeted over the 15 month enrollment and LPI phase. This represents between approximately 8 visits per site. 120 Visits divided by 15 sites equals 8.0 visits per site. Over the fifteen month period, sites will be visited more then once every two months.

	  
	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	
A total of $144,000 is budgeted for travel to sites for monitoring visits.

	  
	
Travel Analysis

	  	
Budgeted Dollars 

For Travel

	  	  	  	  	  	
A total of 8 visits for each of the 15 US based sites is budgeted = 120 total site visits.

	  
	  	  	  	  	  	  	  	  	  	
A total of $1,200 is budgeted for each trip:

	  
	  	  	
$

	
100,800

	  	
paid during enrollment

	  	  	  	
Trip Costs are calculated as follows: $650 for airfare, $300 for two nights lodging,

	  
	  	  	
$

	
36,000

	  	
paid during LPI duration

	  	  	  	
$150 for meals and $100 for all other out of pocket costs.

	  
	  	  	
$

	
7,200

	  	
paid during close out

	  	  	  	
$1,200 x 120 visits = $144,000

	  
	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  
	  	  	
$

	
144,000

	  	
Total Site Monitor Travel Budget

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]